Jody A. Charnow

Editor https://www.cancertherapyadvisor.com

Jody A. Charnow has been the editor of Renal & Urology News, a publication of Haymarket Media, since 2003. Previously, he had served as editor of Internal Medicine World Report and a managing editor for Medical Tribune. He holds a BA in biology from the State University of New York at Albany.

All articles by Jody A. Charnow

Prostate Cancer

Serial SBRT Potentially Beneficial in Oligometastatic Prostate Cancer

Jody A. Charnow

December 2, 2022

Serial stereotactic body radiation therapy directed by PET using novel radiotracers may offer clinical benefits in patients with oligometastatic prostate cancer.

Bladder Cancer

Post-Cystectomy Long-Term Follow-Up Needed Even If No Sign of Bladder Cancer

Jody A. Charnow

November 30, 2022

Recurrence of bladder cancer after radical cystectomy can occur up to 4 years after surgery, a study suggests.

Examining the Pharmacoeconomics of Advanced Prostate Cancer

General Oncology

Medicine vs Food: The Patient Care Dilemma of Financial Toxicity

Jody A. Charnow

November 23, 2022

Physicians are calling on colleagues to bring up the cost of care and its potential impact when discussing treatment options with patients.

Renal Cell Carcinoma

Cytoreductive Nephrectomy Added to ICI Therapy Ups Survival in mRCC

Jody A. Charnow

November 15, 2022

Use of cytoreductive nephrectomy with an immune checkpoint inhibitor reduced the risk of death by 67%.

Bladder Cancer

Enfortumab Vedotin Plus Pembrolizumab “Promising” for Untreated Advanced Urothelial Carcinoma

Jody A. Charnow

October 5, 2022

Patients with advanced urothelial carcinoma treated with first-line enfortumab vedotin plus pembrolizumab had a 93.3% disease control rate.

Prostate Cancer

Metastatic Prostate Cancer: Investigators Ponder New Path to Improve Survival

Jody A. Charnow

October 3, 2022

Novel treatments for metastatic prostate cancer have prolonged lives, but the survival benefits remain modest.

Prostate Cancer

PSMA PET/CT Lymph Node Staging Can Predict Prostate Cancer Surgery Outcomes

Jody A. Charnow

September 30, 2022

Pelvic lymph node metastases visualized on PSMA PET/CT prior to prostate cancer surgery independently predicts an increased risk for biochemical disease progression, a study found.

ESMO 2022

Greater PSA Decline Predicts Better ¹⁷⁷Lu-PSMA-617 Outcomes in mCRPC

Jody A. Charnow

September 26, 2022

PSA decline in men who receive 177Lu-PSMA-617 for mCRPC is associated with radiographic progression and death risk.

Contrary to some news headlines, monitoring prostate cancer has different survival implications than

ESMO 2022

Real-World Data Support Nivolumab + Ipilimumab for First-Line mRCC Therapy

Jody A. Charnow

September 26, 2022

A real-world study revealed an objective response rate consistent with that observed in the CheckMate 214 trial.

ESMO 2022

¹⁷⁷Lutetium-PSMA-617 After ²²³Radium for mCRPC Safe, Effective

Jody A. Charnow

September 22, 2022

Treatment with 177lutetium-PSMA-617 is safe and effective in patients with metastatic castration-resistant prostate cancer who have previously received 223radium.

Next post in ESMO 2022